Data monitoring committee: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import |
||
| Line 36: | Line 36: | ||
{{stub}} | {{stub}} | ||
<gallery> | |||
File:COVID-19_vaccine_announcement_-_51159265899.jpg | |||
</gallery> | |||
Latest revision as of 00:58, 17 February 2025
Data Monitoring Committee (DMC), also known as Data and Safety Monitoring Board (DSMB), is a group of independent experts who monitor patient safety and treatment efficacy data while a clinical trial is ongoing.
Role and Responsibilities[edit]
The primary role of a DMC is to ensure the safety of trial participants and the validity and integrity of data in a clinical trial. The DMC has the authority to recommend continuation, modification, or termination of a trial based on the observed beneficial or adverse effects of the treatment under study.
The responsibilities of a DMC include:
- Reviewing the clinical trial protocol and plans for data analysis.
- Monitoring the rate of enrollment, dropout, and missing data.
- Evaluating the quality of data collected.
- Monitoring the overall conduct of the trial.
- Reviewing accumulated data from the trial and deciding whether it is ethical to continue, modify, or stop the trial.
Composition[edit]
A DMC typically consists of clinical trial experts, statisticians, and clinicians knowledgeable about the disease and treatment under study. It may also include bioethicists and patient representatives. The members should have no financial, scientific, or other conflict of interest with the trial.
Meetings[edit]
DMC meetings are usually held in private, and the frequency of meetings depends on the type of trial, the rate of enrollment, and the rate of occurrence of endpoints. The DMC reviews reports prepared by a statistical data analysis center, which is separate from the trial investigators and sponsor.
Confidentiality[edit]
The DMC has access to unblinded trial data, which must be kept confidential to maintain the integrity of the trial. The DMC's recommendations are usually communicated to the trial sponsor and investigators through a formal letter.


